BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Büning C, Lochs H. Conventional therapy for Crohn’s disease. World J Gastroenterol 2006; 12(30): 4794-4806 [PMID: 16937460 DOI: 10.3748/wjg.v12.i30.4794]
URL: https://www.wjgnet.com/1007-9327/full/v12/i30/4794.htm
Number Citing Articles
1
Javier P. Gisbert, Fernando Gomollón. Errores frecuentes en el manejo del paciente ambulatorio con enfermedad inflamatoria intestinalGastroenterología y Hepatología 2007; 30(8): 469 doi: 10.1157/13110491
2
Sharon Dudley-Brown, Arpita Nag, Cory Cullinan, Mary Ayers, Steve Hass, Sumeet Panjabi. Health-Related Quality-of-Life Evaluation of Crohn Disease Patients After Receiving Natalizumab TherapyGastroenterology Nursing 2009; 32(5): 327 doi: 10.1097/SGA.0b013e3181bb1484
3
Mahnaz Fatahzadeh. Inflammatory bowel diseaseOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2009; 108(5): e1 doi: 10.1016/j.tripleo.2009.07.035
4
Dorota Wójcik-Pastuszka, Aleksandra Potempa, Witold Musiał. Bipolymeric Pectin Millibeads Doped with Functional Polymers as Matrices for the Controlled and Targeted Release of MesalazineMolecules 2020; 25(23): 5711 doi: 10.3390/molecules25235711
5
G. Rogler. Inflammatory Bowel Disease — Diagnostic and Therapeutic StrategiesFalk Symposium 2007; 154: 165 doi: 10.1007/978-1-4020-6116-5_18
6
J. Gapasin, D. R. Van Langenberg, G. Holtmann, D. J. Hetzel, J. M. Andrews. Potentially avoidable surgery in inflammatory bowel disease: what proportion of patients come to resection without optimal preoperative therapy? A guidelines‐based auditInternal Medicine Journal 2012; 42(5) doi: 10.1111/j.1445-5994.2010.02328.x
7
Claudia Pena Rossi, Stephen B Hanauer, Ratko Tomasevic, John O Hunter, Ira Shafran, Hans Graffner. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding studyBMC Gastroenterology 2009; 9(1) doi: 10.1186/1471-230X-9-22
8
Ira Shafran, Patricia Burgunder. Adjunctive Antibiotic Therapy with Rifaximin May Help Reduce Crohn’s Disease ActivityDigestive Diseases and Sciences 2010; 55(4): 1079 doi: 10.1007/s10620-009-1111-y
9
Ichiro Moriyama, Shunji Ishihara, M Azharul Karim Rumi, M D Monowar Aziz, Yoshiyuki Mishima, Naoki Oshima, Chikara Kadota, Yasunori Kadowaki, Yuji Amano, Yoshikazu Kinoshita. Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitisLaboratory Investigation 2008; 88(6): 652 doi: 10.1038/labinvest.2008.38
10
Javier P. Gisbert, Fernando Gomollón. Errores frecuentes en el manejo del paciente grave con enfermedad inflamatoria intestinalGastroenterología y Hepatología 2007; 30(5): 294 doi: 10.1157/13101982